Rosetta and NYU form melanoma pact:
This article was originally published in Clinica
Executive Summary
Rosetta Genomics has joined up with the NYU Medical Center to develop a diagnostic test for melanoma, using Rosetta's microRNA technology. The partnership will involve the use of Rosetta's diagnostic engine to screen more than 700 microRNAs in order to identify a diagnostic signature for the disease. The collaborators hope to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients, and to predict the risk that the cancer will metastasise. Rehovot, Israel-based Rosetta already has a pact with US-based NYU to develop a line of early detection products for lung and mesothelioma cancers. The firm also hopes to launch three novel tests during 2008, one for cancer of unknown primary (CUP) and two for lung cancer.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.